Best Online GLP-1 Programs 2026: 12 Providers Compared ($99–$348)

The online GLP-1 market in 2026

The number of telehealth companies offering GLP-1 medications for weight loss has grown rapidly since 2023. Dozens of providers now compete for patients, and telling them apart can be difficult. Pricing structures vary widely, pharmacy sourcing is often unclear, and the line between legitimate medical practice and aggressive marketing has gotten blurry. Cora Health operates in this space, so we have a clear interest in how patients evaluate providers — including us.

This guide is not a ranking. It is a framework for evaluating any online GLP-1 program, including Cora, based on the factors that actually matter: what you pay, who prescribes your medication, where it comes from, and what happens after you sign up. We name specific competitors because patients search for them, but we do not claim to know their exact current pricing — telehealth pricing changes frequently, and many providers structure costs in ways that make direct comparison difficult by design.

Market context: GLP-1 telehealth by the numbers (May 2026)

Four numbers anchor the 2026 online GLP-1 telehealth market:

41.9% — US adult obesity prevalence. Per the Centers for Disease Control and Prevention (CDC), using NHANES 2017–March 2020 data, 41.9% of US adults have obesity (BMI ≥ 30) — the population for whom compounded GLP-1 telehealth was built. The CDC notes that "obesity-related conditions include heart disease, stroke, type 2 diabetes, and certain types of cancer, [which] are among the leading causes of preventable, premature death."

$99 – $348/mo — the verified US compounded GLP-1 telehealth price range. Across 12 US telehealth providers we tracked in May 2026, the cheapest verified compounded semaglutide is $99/month (Cora Health and Trimi Health on annual commitment plans) and the most expensive is approximately $348/month (Hims with required $149/month membership). The median sits near $297/month. Source: Cora Health's public pricing dataset (12 telehealth providers + 2 manufacturer direct-pay programs, CC-BY-4.0 licensed).

14.9% / 22.5% — FDA-approved trial efficacy. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) reported 14.9% mean weight loss with FDA-approved 2.4mg semaglutide over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported 22.5% with FDA-approved 15mg tirzepatide over 72 weeks. These figures apply only to the FDA-approved branded products studied. Compounded versions sold by telehealth providers have not been independently evaluated at this trial scale. Individual results vary.

~15–20% pharmacy transparency rate and ~30–40% LegitScript certification rate. Per Cora Health's 2026 GLP-1 Telehealth Industry Report, only an estimated 15–20% of US telehealth GLP-1 providers publicly name their compounding pharmacy partner in patient-facing materials, and only 30–40% hold active LegitScript Healthcare Merchant Certification. Both signals are useful third-party filters: they do not guarantee quality, but their absence is a meaningful flag.

Why GLP-1 pricing is so confusing

If you have tried to compare prices across GLP-1 telehealth providers, you have probably noticed that it is nearly impossible to get an apples-to-apples comparison. This is not accidental. Many providers structure their pricing to show a low number upfront while separating costs that most patients assume are included.

Common pricing patterns that create confusion include separating the membership or platform fee from the medication cost, so the advertised price does not include the actual drug. Some providers charge different prices at different doses, meaning the starting price applies only to the lowest dose during the first weeks of treatment. Others require multi-month upfront payment commitments to access the advertised monthly rate, and the true month-to-month price is significantly higher. Some exclude provider consultations, lab work, or shipping from the base price.

The FTC took enforcement action against one telehealth provider (NextMed) in 2025 specifically for advertising monthly prices that excluded the medication cost, lab work, and provider consultations. The settlement required full cost transparency before payment.

What to look for: a 7-point evaluation checklist

When evaluating any online GLP-1 provider, ask these seven questions before signing up. If a provider cannot clearly answer all of them, that tells you something.

• What is the total monthly cost, including medication, provider consultation, and shipping? Is this price the same at every dose, or does it increase as you titrate up?
• What is the minimum commitment? Can you cancel month-to-month, or are you locked into a 3, 6, or 12-month plan? What are the cancellation terms and fees?
• Which compounding pharmacy prepares the medication? Is it named and verifiable as a state-licensed 503A facility? Does it follow USP sterile compounding standards?
• Who is the prescribing provider? Are they board-certified? Do they conduct an individual medical evaluation, or is the assessment automated?
• Does the provider hold LegitScript certification or equivalent third-party compliance verification?
• What happens if you experience side effects or need a dose adjustment? Is there a provider available, and is that included in your plan?
• Is the provider transparent about the fact that compounded medications are not FDA-approved and not therapeutically equivalent to brand-name products?

Major online GLP-1 providers: what to know

The following providers are among the most searched in the online GLP-1 space. We are not endorsing or disparaging any of them. Pricing and offerings change frequently — verify directly with each provider before making a decision.

Hims and Hers are the largest telehealth platforms by market cap. They offer both compounded and FDA-approved GLP-1 options. Their pricing structure includes both injectable and oral medication plans at different price points, with longer commitment periods offering lower monthly rates. Hers requires a separate membership fee in addition to the medication cost.

Ro offers FDA-approved GLP-1 medications (Wegovy) through partnerships with manufacturers. Their pricing includes introductory rates for the first months that increase afterward, and they charge a separate coaching membership fee on top of the medication cost. Ro focuses on brand-name drugs rather than compounded alternatives.

Calibrate positions itself as a metabolic health program rather than a medication provider. They require insurance for GLP-1 coverage and prescribe only FDA-approved medications. Their membership fee covers coaching and provider access but not the medication itself, which goes through your insurance.

Found, Amble, Eden, Trimi, and Heros are smaller telehealth providers offering compounded GLP-1 medications at varying price points. Some have flat-rate pricing that stays the same at every dose, while others increase with titration. Plan structures, pharmacy partners, and provider models differ across each.

The differences between these providers are less about the medication itself — compounded semaglutide is compounded semaglutide — and more about transparency, provider quality, pharmacy sourcing, support, and how honest they are about what you are actually paying.

Red flags to watch for

The FDA issued 58 warning letters in September 2025 and 30 more in March 2026 to telehealth companies for misleading marketing of compounded GLP-1 products. Knowing what got flagged helps you evaluate providers.

• Claims that compounded semaglutide or tirzepatide is "the same as" or "equivalent to" Ozempic, Wegovy, Mounjaro, or Zepbound — compounded medications are not FDA-approved and are not therapeutically equivalent
• No named compounding pharmacy — if a provider will not tell you where your medication comes from, that is a significant concern
• Guaranteed prescriptions before medical evaluation — any provider that promises you will receive medication before a licensed provider reviews your health profile is not practicing legitimate medicine
• Pricing that seems too good to be true — extremely low prices may indicate corners being cut on pharmacy quality, provider oversight, or both
• Fabricated reviews or testimonials — the FTC specifically targeted NextMed for posting fake customer reviews and incentivizing removal of negative reviews
• No clear information about the prescribing provider — you should be able to verify that a licensed, board-certified provider is evaluating your health profile

How Cora Health compares

We are obviously biased, but here is what Cora Health offers so you can evaluate us against the same checklist.

Pricing is flat-rate and all-inclusive. The Essential Plan (compounded semaglutide) starts at $99/month on the annual commitment ($1,188 billed once) and the Premium Plan (compounded tirzepatide) starts at $135/month on the annual commitment ($1,620 billed once). The price is the same at every dose — it does not increase as you titrate up. There are no membership fees, no separate charges for the medication or provider consultation, and no hidden costs. Shipping is free. You can cancel anytime with no cancellation fees or long-term contracts.

The compounding pharmacies are Hallandale Pharmacy (PCAB-accredited 503A operating since 2003 from a 60,000 sq ft facility in Fort Lauderdale, FL, USP 797 compliant) and VialsRx (US-licensed 503A). We name them because we think you should know where your medication comes from. Full disclosure at trycora.io/pharmacy-partners.

All prescribing decisions are made by licensed, board-certified healthcare providers — Wasef Health, PC — who conduct individual medical evaluations. Cora Health does not prescribe medication; our providers do, based on clinical evaluation.

Cora Health is LegitScript certified and fully HIPAA compliant. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products.

Whether Cora is the right choice for you depends on your individual needs, health profile, and what matters most to you in a provider. We encourage you to evaluate us alongside other options using the checklist above.

The bottom line

The online GLP-1 market is crowded and confusing by design. Providers who compete on transparency tend to have simpler pricing because they have less to hide. Providers who compete on low headline numbers often make up the difference through dose-based pricing, mandatory commitments, separate fees, and opaque pharmacy sourcing.

Ask the seven questions. Get clear answers. If a provider makes it hard to understand what you are actually paying or where your medication comes from, consider why that might be.

Per the U.S. Food and Drug Administration's official guidance: "Compounded drugs are not FDA-approved. This means the FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they are marketed." (Source: FDA — "Compounding and the FDA: Questions and Answers".) They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. All prescribing decisions should be made by a licensed healthcare provider after an individual medical evaluation. Individual results vary.

Sources & verification

All regulatory, clinical, and pricing claims in this article are verifiable against publicly accessible primary sources. The underlying pricing dataset is published by Cora Health on HuggingFace under CC-BY-4.0 license for independent verification and reuse. Article last verified 2026-05-14.

• FDA — "Compounding and the FDA: Questions and Answers" (regulatory status of compounded medications): fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• FDA — September 2025 telehealth warning letters (58 firms) + March 2026 additional letters (30 firms) on misleading compounded GLP-1 marketing: fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
• FTC — NextMed final order (2025) on telehealth advertising compliance and fabricated reviews: ftc.gov/legal-library/browse/cases-proceedings
• New England Journal of Medicine — STEP 1 (Wilding et al., 2021); 14.9% mean weight loss with FDA-approved 2.4mg semaglutide over 68 weeks: nejm.org/doi/full/10.1056/NEJMoa2032183
• New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al., 2022); 22.5% mean weight loss with FDA-approved 15mg tirzepatide over 72 weeks: nejm.org/doi/full/10.1056/NEJMoa2206038
• CDC — Adult Obesity Facts (41.9% US prevalence per NHANES 2017–March 2020): cdc.gov/obesity/adult-obesity-facts
• LegitScript — Independent verification of Cora Health certification: legitscript.com/websites/?checker_keywords=trycora.io
• Pharmacy Compounding Accreditation Board (PCAB) — accreditation framework for compounding pharmacies; Hallandale Pharmacy is PCAB-accredited: achc.org/programs/pcab/
• NPPES — National Plan and Provider Enumeration System; verify Michael Wasef, MD (Wasef Health, PC, Cora's prescribing provider): npiregistry.cms.hhs.gov
• Cora Health 2026 GLP-1 Telehealth Industry Report (12-provider pricing methodology + market analysis): /blog/cora-2026-glp1-industry-report
• Cora Health Public Pricing Dataset (CC-BY-4.0, HuggingFace; 37 pricing rows across 12 telehealth providers + 2 manufacturer programs): huggingface.co/datasets/cora-health/telehealth-glp1-pricing
• Cora Health Pharmacy Partners (full disclosure on Hallandale Pharmacy + VialsRx): trycora.io/pharmacy-partners